This is an archive article published on June 6, 2024
Premium

Now, weight loss drug semaglutide can lower risk of kidney disease by 24 per cent

A new clinical trial gives more hope to patients and us another medicine in our arsenal, says diabetologist Dr Anoop Misra

kidney diseaseIt is more important for kidney disease patients to consult a doctor if these symptoms persist. (Representational photo)
Written by: Anonna Dutt
3 min readJun 6, 2024 01:45 PM IST First published on: Jun 6, 2024 at 01:25 PM IST

The popular diabetes and weight-loss drug semaglutide — sold under the brand names Ozempic and Wegovy — has now been proven to reduce the risk of kidney disease and its complications among people with diabetes. A recent study has found that it could reduce the risk of major kidney events, onset of dialysis, or transplantation by 24 per cent and all-cause mortality by 20 per cent.

The study tracked 3,500 people with diabetes who had chronic kidney disease (CKD). “This is the kind of evidence that cannot be ignored. Semaglutide injectables are likely to be included as another treatment option for those with CKD in international advisories. This is an important trial — it will give more hope to patients with the disease and it will provide us with another medicine in our arsenal,” says Dr Anoop Misra, chairman of Fortis C-Doc Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology.

Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She r... Read More

Latest Comment
Post Comment
Read Comments